Wang, J., & Yan, S. Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma. Frontiers Media S.A.
Chicago Style (17th ed.) CitationWang, Jingyuan, and Shuai Yan. Integration of Histone Modification-based Risk Signature with Drug Sensitivity Analysis Reveals Novel Therapeutic Strategies for Lower-grade Glioma. Frontiers Media S.A.
MLA (9th ed.) CitationWang, Jingyuan, and Shuai Yan. Integration of Histone Modification-based Risk Signature with Drug Sensitivity Analysis Reveals Novel Therapeutic Strategies for Lower-grade Glioma. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.